Aurinia Pharmaceuticals (AUPH) revenue breakdown
By product, Net product sales is the largest at 96% of fiscal 2025 revenue, growing 279% a year over 5 years.
By region, U.S. is the largest at 93% of fiscal 2025 revenue, growing 231% a year over 6 years.
Revenue by product
Fiscal years, as Aurinia Pharmaceuticals reports them in its 10-K filings; fiscal 2025 total $283M.
| Products | 2018 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|
| Net product sales | $345,000 | $45M | $103M | $159M | $216M | $271M | 96% |
| License, collaboration and royalty revenue | $118,000 | $117,000 | $31M | $17M | $19M | $12M | 4% |
Revenue by region
Fiscal years, as Aurinia Pharmaceuticals reports them in its 10-K filings; fiscal 2025 total $283M.
| Regions | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| U.S. | — | — | $200,000 | — | $45M | $102M | $158M | $210M | $264M | 93% |
| Japan | — | — | — | $50M | — | $31M | $18M | $25M | $19M | 7% |
| United States | $300,000 | $345,000 | — | — | — | — | — | — | — | — |
| Other | $118,000 | $118,000 | $118,000 | $118,000 | $117,000 | — | — | — | — | — |
| Other | — | — | — | — | — | $89,000 | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for AUPH.
Open AUPH in InvestinglyQuestions
Where does Aurinia Pharmaceuticals make its money?
In fiscal 2025, by product: Net product sales $271M, License, collaboration and royalty revenue $12M.
From Aurinia Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.